Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.


Journal

Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647

Informations de publication

Date de publication:
03 2019
Historique:
received: 20 12 2018
pubmed: 5 1 2019
medline: 26 11 2019
entrez: 5 1 2019
Statut: ppublish

Résumé

A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology that precedes neuronal death and symptom onset, would be a much-needed prognostic biomarker. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins. In this study, we aimed to identify and validate novel CSF biomarkers of synapse loss in AD. Discovery: Combining shotgun proteomics of the CSF with an exhaustive search of the literature and public databases, we identified 251 synaptic proteins, from which we selected 22 for further study. Verification: Twelve proteins were discarded because of poor detection by Selected Reaction Monitoring (SRM). We confirmed the specific expression of 9 of the remaining proteins (Calsynytenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at the human synapse using Array Tomography microscopy and biochemical fractionation methods. Exploration: Using SRM, we monitored these 9 synaptic proteins (20 peptides) in a cohort of CSF from cognitively normal controls and subjects in the pre-clinical and clinical AD stages (

Identifiants

pubmed: 30606734
pii: S1535-9476(20)31857-0
doi: 10.1074/mcp.RA118.001290
pmc: PMC6398205
doi:

Substances chimiques

Biomarkers 0
CLSTN1 protein, human 0
Calcium-Binding Proteins 0
Nerve Tissue Proteins 0
Receptors, AMPA 0
STX1B protein, human 0
Syntaxin 1 0
Thy-1 Antigens 0
glutamate receptor ionotropic, AMPA 4 0
neurexin IIIalpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

546-560

Informations de copyright

© 2019 Lleó et al.

Références

J Proteome Res. 2005 May-Jun;4(3):725-33
pubmed: 15952719
Mol Neurobiol. 2005 Dec;32(3):237-49
pubmed: 16385140
Biol Open. 2012 Aug 15;1(8):761-74
pubmed: 23213470
Mult Scler Int. 2011;2011:246412
pubmed: 22096631
J Neurosci. 2014 Jan 15;34(3):804-16
pubmed: 24431439
J Biol Chem. 2004 Jan 9;279(2):987-1002
pubmed: 14532281
Mol Cell Proteomics. 2010 Sep;9(9):2063-75
pubmed: 20811074
Alzheimers Res Ther. 2018 Jan 15;10(1):5
pubmed: 29370833
Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
J Biol Chem. 2013 Nov 29;288(48):34906-19
pubmed: 24136198
Alzheimers Dement. 2015 Oct;11(10):1180-90
pubmed: 25533203
Proteomics. 2009 Jun;9(12):3303-15
pubmed: 19562802
Mol Neurodegener. 2015 Apr 09;10:18
pubmed: 25881291
PLoS Biol. 2015 Oct 05;13(10):e1002267
pubmed: 26437117
Science. 2002 Oct 25;298(5594):789-91
pubmed: 12399581
Neurobiol Aging. 2013 Jun;34(6):1653-61
pubmed: 23273601
Neuron. 2015 Jan 7;85(1):173-189
pubmed: 25569349
PLoS One. 2015 Sep 25;10(9):e0138950
pubmed: 26407320
Alzheimers Res Ther. 2016 Oct 3;8(1):41
pubmed: 27716408
Science. 1992 Jul 10;257(5067):255-9
pubmed: 1321498
Nat Genet. 2014 Dec;46(12):1327-32
pubmed: 25362483
Brain Struct Funct. 2017 Dec;222(9):4149-4161
pubmed: 28643105
Neurobiol Aging. 2005 Feb;26(2):207-27
pubmed: 15582749
Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1038-43
pubmed: 18195348
J Comp Neurol. 1999 Jul 26;410(2):256-64
pubmed: 10414531
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Cell. 2013 Jul 3;154(1):75-88
pubmed: 23827676
Bioinformatics. 2014 Sep 1;30(17):2524-6
pubmed: 24794931
J Neurosci. 2014 Jun 25;34(26):8716-27
pubmed: 24966372
Science. 2014 May 30;344(6187):1023-8
pubmed: 24876496
J Proteome Res. 2006 Oct;5(10):2769-79
pubmed: 17022648
Mol Cell Neurosci. 2001 Jan;17(1):226-40
pubmed: 11161481
Brain. 2017 Dec 1;140(12):3204-3214
pubmed: 29177427
J Neurochem. 2005 Mar;92(6):1306-16
pubmed: 15748150
Proteomics. 2004 Oct;4(10):3141-55
pubmed: 15378707
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11999-2004
pubmed: 20547835
Mol Cell Proteomics. 2006 Jun;5(6):1158-70
pubmed: 16507876
J Neurochem. 2014 Nov;131(3):268-83
pubmed: 25040546
PLoS One. 2010 Jun 11;5(6):e10980
pubmed: 20552007
J Neuropathol Exp Neurol. 1992 Mar;51(2):133-41
pubmed: 1347079
J Neurosci. 2014 Feb 12;34(7):2702-12
pubmed: 24523559
PLoS One. 2012;7(8):e42555
pubmed: 22880031
Neuropharmacology. 2014 Apr;79:172-9
pubmed: 24445080
Nat Neurosci. 2011 Jan;14(1):19-21
pubmed: 21170055
Cell. 2004 Dec 29;119(7):1013-26
pubmed: 15620359
Neuron. 2014 May 21;82(4):756-71
pubmed: 24853936
Alzheimers Dement. 2013 May;9(3):251-61
pubmed: 23622690
Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3833-8
pubmed: 15007177
Brain Res. 2010 Nov 29;1362:13-22
pubmed: 20875798
J Neurosci. 2014 May 21;34(21):7266-80
pubmed: 24849359
PLoS One. 2012;7(10):e46683
pubmed: 23071613
Neurology. 2015 Aug 18;85(7):626-33
pubmed: 26180139
Mol Neurodegener. 2014 Nov 23;9:53
pubmed: 25418885
Neuron. 2013 Apr 24;78(2):285-97
pubmed: 23622064
Synapse. 2017 Jun;71(6):
pubmed: 28196395
Neuroscience. 2004;128(2):219-28
pubmed: 15350635
Eur J Neurosci. 1996 Oct;8(10):2068-74
pubmed: 8921297
Mol Syst Biol. 2009;5:269
pubmed: 19455133
Nature. 2004 Feb 26;427(6977):801
pubmed: 14985749
J Cell Biol. 1998 Feb 9;140(3):685-98
pubmed: 9456327
J Neurochem. 2009 Feb;108(3):662-75
pubmed: 19187093
Am J Hum Genet. 2012 Jan 13;90(1):133-41
pubmed: 22209245
Pain. 2016 Jun;157(6):1314-24
pubmed: 26859820
J Neurosci. 2009 May 20;29(20):6479-89
pubmed: 19458219
PLoS One. 2009;4(4):e5230
pubmed: 19381277
PLoS One. 2015 Oct 21;10(10):e0140868
pubmed: 26488171
J Neurosci. 2000 Jun 1;20(11):4069-80
pubmed: 10818142
J Proteome Res. 2004 Jan-Feb;3(1):97-103
pubmed: 14998169
Mol Cell Proteomics. 2014 Nov;13(11):3152-63
pubmed: 25038066
Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1469-73
pubmed: 8641850
J Alzheimers Dis. 2010;21(2):655-66
pubmed: 20571220
Nat Neurosci. 2014 Jan;17(1):56-64
pubmed: 24336150
Neuropathol Appl Neurobiol. 2016 Feb;42(1):77-94
pubmed: 26613567
Mol Cell Neurosci. 2001 Jan;17(1):151-66
pubmed: 11161476
Mol Cell Neurosci. 2005 Jan;28(1):128-40
pubmed: 15607948
J Biol Chem. 2000 Dec 22;275(51):39803-6
pubmed: 11036064
Cell. 2006 Nov 17;127(4):831-46
pubmed: 17110340
J Biol Chem. 2004 May 14;279(20):21003-11
pubmed: 15020595
Clin Proteomics. 2016 May 15;13:11
pubmed: 27186164
Int Rev Neurobiol. 2006;73:29-98
pubmed: 16737901
Expert Opin Ther Targets. 2016 Oct;20(10):1195-207
pubmed: 27167520
J Neurosci Res. 1999 Aug 1;57(3):315-23
pubmed: 10412022
Hum Mol Genet. 2011 Aug 1;20(15):3042-51
pubmed: 21551456
Exp Mol Med. 2013 Sep 06;45:e39
pubmed: 24008896
J Biol Chem. 2017 May 5;292(18):7327-7337
pubmed: 28283575
J Neurochem. 2006 Apr;97 Suppl 1:16-23
pubmed: 16635246
Cell. 2000 Jun 9;101(6):657-69
pubmed: 10892652
Hum Mol Genet. 2012 Jul 1;21(13):2845-54
pubmed: 22434822
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Proteomics. 2015 Apr 24;119:90-9
pubmed: 25661039
Mol Brain. 2014 Nov 28;7:88
pubmed: 25429717
J Proteome Res. 2005 Mar-Apr;4(2):306-15
pubmed: 15822905
J Neurochem. 2005 Dec;95(6):1732-45
pubmed: 16269012
Mol Cell Neurosci. 2014 Mar;59:106-18
pubmed: 24534009
J Alzheimers Dis. 2017;58(3):909-918
pubmed: 28527215
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Neurobiol Aging. 2014 Apr;35(4):746-56
pubmed: 24211009
Nature. 1996 Feb 29;379(6568):826-9
pubmed: 8587606

Auteurs

Alberto Lleó (A)

From the ‡Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain; alleo@santpau.cat.
§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Raúl Núñez-Llaves (R)

§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Daniel Alcolea (D)

From the ‡Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Cristina Chiva (C)

‖Proteomics Unit, Center for Genomics Regulation, Barcelona Institute of Science and Technology, 08003 Barcelona.
**University Pompeu Fabra, 08003 Barcelona.

Daniel Balateu-Paños (D)

¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Martí Colom-Cadena (M)

§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Gemma Gomez-Giro (G)

¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Laia Muñoz (L)

§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Marta Querol-Vilaseca (M)

§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Jordi Pegueroles (J)

§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Lorena Rami (L)

‡‡Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 08015 Barcelona, Spain.

Albert Lladó (A)

‡‡Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 08015 Barcelona, Spain.

José L Molinuevo (JL)

‡‡Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 08015 Barcelona, Spain.

Mikel Tainta (M)

§§Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, 20009 San Sebastian, Spain.
¶¶Servicio de Neurologia, Organización Sanitaria Integrada Goierri-Alto Urola, Osakidetza, Zumárraga, España.

Jordi Clarimón (J)

§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Tara Spires-Jones (T)

‖‖Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh EH8 9JZ, UK.

Rafael Blesa (R)

From the ‡Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Juan Fortea (J)

From the ‡Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Pablo Martínez-Lage (P)

§§Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, 20009 San Sebastian, Spain.

Raquel Sánchez-Valle (R)

‡‡Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 08015 Barcelona, Spain.

Eduard Sabidó (E)

‖Proteomics Unit, Center for Genomics Regulation, Barcelona Institute of Science and Technology, 08003 Barcelona.
**University Pompeu Fabra, 08003 Barcelona.

Àlex Bayés (À)

***Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025, Barcelona, Spain.
‡‡‡Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain.

Olivia Belbin (O)

§Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain; obelbin@santpau.cat.
¶Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH